Retrophin doses first patient in Phase III trial of RE-024 for PKAN

Retrophin has started dosing patients in a Phase III Fosmetpantotenate Replacement Therapy (FORT) clinical trial of RE-024 to treat patients with pantothenate kinase-associated neurodegeneration (PKAN).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news